Citigroup keeps Ovintiv at Buy and lifts price target to $74
Citigroup maintained its Buy rating on Ovintiv and raised its price target from $68 to $74, an 8.8% increase. The source is TradingView.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
Citigroup kept its Buy rating on oil and gas producer Ovintiv and raised its price target from $68 to $74, an increase of 8.8%. According to TradingView, the new target implies a rise of 13.2% from the November 13 closing price of $65.39.
For comparison, across the five most recent analyst notes over the past 30 days, Ovintiv price targets range from $77 to $90. Barclays kept its Overweight rating with a $85 target on November 13, Truist Securities maintained Buy at $90 on November 5, and Wells Fargo kept Overweight at $81 the same day.
why it matters
Price target revisions like this usually reflect analysts' expectations for the company's earnings and asset value, but on their own they rarely change the broader picture for the sector. For energy investors, oil and gas price trends and Ovintiv's operating results matter more. The item is routine and concerns a single stock.
tags
instruments
sources
- Citigroup maintains Ovintiv at Buy, raises price target to $74 from $68 — TradingView, 13 November 2026 at 21:21 UTC
- Citigroup maintains SpyGlass Pharma at Buy, raises price target to $45 from $42 — TradingView, 13 November 2026 at 21:23 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗